A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2060
- SGS Life Science Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female of non-childbearing potential (postmenopausal or permanently sterile)
- Have a body mass index (BMI) between 19 and 30 kilogram per meter square (kg/m^2) (BMI = weight/height^2), and a body weight of 50 to 100 kilogram (kg), inclusive
- Healthy on the basis of medical history, a physical examination, vital signs, and 12 lead electrocardiogram (ECG) performed at screening
- Healthy on the basis of clinical laboratory tests performed at screening and Day -1
- A woman must have a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test on Day -1
Exclusion Criteria:
- Has history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
- Has a disease or disease treatment associated with immune suppression or lymphopenia, these include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenism, and chronic granulomatous disease
- Has a personal history of or conditions associated with thromboembolic events or bleeding disorders, including (but not limited to) myocardial infarction (MI), cerebral vascular accident (CVA)/stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), hemophilia, or menometrorrhagia
- Has history of allergy or adverse reactions to shellfish, aluminum, aluminum hydroxide keyhole limpet hemocyanin (KLH), tetanus or tetanus toxoid or its excipients
- Has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-64232025 and its excipients used in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single Ascending Dose (SAD) IV Cohort
Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
|
JNJ-64232025 will be administered as IV infusion.
Matching placebo will be administered as IV infusion or SC injection.
|
|
Experimental: Subcutaneous (SC) Cohort
Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
|
Matching placebo will be administered as IV infusion or SC injection.
JNJ-64232025 will be administered as SC injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAE) by Severity
Time Frame: Up to Day 113
|
An adverse event (AE) is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
The severity of the TEAEs will be assessed as mild, moderate, or severe.
|
Up to Day 113
|
|
Number of Participants with Serious Adverse Events (SAE)
Time Frame: Up to Day 113
|
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Up to Day 113
|
|
Number of Participants with Clinically Significant Changes in Vital Signs
Time Frame: Up to Day 113
|
Number of participants with clinically significant changes in the vital signs including temperature, pulse/heart rate, respiratory rate, and blood pressure will be reported.
|
Up to Day 113
|
|
Number of Participants with ECG Abnormalities
Time Frame: Up to Day 113
|
Number of participants with electrocardiogram (ECG) abnormalities will be reported.
|
Up to Day 113
|
|
Number of Participants with Clinical Laboratory Abnormalities
Time Frame: Up to Day 113
|
Number of participants with clinical laboratory abnormalities, including cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viral loads, will be reported.
|
Up to Day 113
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of JNJ-64232025
Time Frame: Up to Day 113
|
The Cmax is the maximum observed plasma concentration of JNJ-64232025.
|
Up to Day 113
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-64232025
Time Frame: Up to Day 113
|
The Tmax is defined as actual sampling time to reach maximum observed plasma concentration of JNJ-64232025.
|
Up to Day 113
|
|
Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity with Extrapolation of the Terminal Phase (AUC[0-infinity])
Time Frame: Up to Day 113
|
The AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(0-last) and C(0-last)/lambda(z); wherein AUC(0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Up to Day 113
|
|
Area Under the Plasma Concentration-Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last])
Time Frame: Up to Day 113
|
The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
|
Up to Day 113
|
|
Terminal Half-Life (t1/2)
Time Frame: Up to Day 113
|
The t1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Up to Day 113
|
|
Total Systemic Clearance (C/L)
Time Frame: Up to Day 113
|
Systemic clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).
|
Up to Day 113
|
|
Apparent Total Systemic Clearance After Extravascular Administration (CL/F)
Time Frame: Up to Day 113
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
CL/F is the apparent total systemic clearance after extravascular administration.
|
Up to Day 113
|
|
Volume of Distribution Based on Terminal Phase (Vz)
Time Frame: Up to Day 113
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
|
Up to Day 113
|
|
Apparent Volume of Distribution Based on Terminal Phase After Extravascular Administration (Vz/F)
Time Frame: Up to Day 113
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.
|
Up to Day 113
|
|
Relative SC Bioavailability (F%)
Time Frame: Up to Day 113
|
Relative SC bioavailability will be calculated using the following equation: F (%[percent]) = AUC(0-infinity),SC/ mean AUC(0-infinity),IV *100%.
|
Up to Day 113
|
|
Number of Participants with Anti-JNJ 64232025 Antibodies
Time Frame: Up to Day 113
|
Number of participants with anti-JNJ-64232025 antibodies will be assessed.
|
Up to Day 113
|
|
Number of Participants with Anti-KLH and Anti-Tetanus Antibodies
Time Frame: Up to Day 113
|
Number of participants with antibodies to anti-Keyhole Limpet Hemocyanin (KLH) and anti-tetanus will be assessed.
|
Up to Day 113
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CR108448
- 2017-003986-82 (EudraCT Number)
- 64232025ARA1001 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.